Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2020, vol. 29, nr 1, January, p. 85–90

doi: 10.17219/acem/92916

Publication type: original article

Language: English

License: Creative Commons Attribution Non-Commercial License

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Moderate-to-severe ovarian hyperstimulation syndrome: A retrospective multivariate logistic regression analysis in Chinese patients

Tianzhong Ma1,A,D,E, Yanru Niu1,C, Bing Wei1,A,F, Lihua Xu1,B, Lin Zou1,B,D, Xiaoqun Che1,B, Xiao Wang1,A,F, Di Tang1,B,E, Riyan Huang1,C,D, Bi Chen1,A,E,F

1 Reproductive Medicine Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China

Abstract

Background. Ovarian hyperstimulation syndrome (OHSS), a life-threatening complication occurring in stimulated ovarian cycles, arises from treatment with gonadotropin for inducing follicular maturation.
Objectives. The aim of this study was to compare the risk factors between patients with severe OHSS and those without OHSS after in vitro fertilization by intracytoplasmatic sperm injection/embryo transfer (IVF-ICSI/ET). Identifying the associated risk factors may provide guidance for clinicians on how to prevent OHSS.
Material and Methods. The retrospective study involved patients who had completed IVF-ICSI/ET cycles. The difference in markers for predicting the occurrence of OHSS between groups was compared. The potential protective and risk factors, as well as the predictive markers, were identified.
Results. Patients with OHSS were younger (p = 0.015), had higher basal antral follicle counts (AFC) (p < 0.001) and lower total dosages of gonadotropin (Gn) (p = 0.011). On the day of human chorionic gonadotropin (hCG) administration, significantly higher total numbers of follicles (p < 0.001), serum estradiol (E2) (p < 0.001) and progestrone (Pg) (p = 0.001) levels, numbers of oocytes (p < 0.001) and metaphase II (MII) oocytes (p < 0.001) were also observed in the OHSS group when compared to the non-OHSS group. A univariate regression analysis revealed that age (OR = 0.898, 95% CI = 0.822–0.981) and total dosage of Gn (OR = 0.999, 95% CI = 0.999–1.000) were protective factors, whereas AFC (OR = 1.090, 95% CI = 1.051–1.131) and, on the day of hCG injection, the number of follicles (OR = 1.185, 95% CI = 1.027–1.230), serum E2 (OR = 1.000, 95% CI = 1.000–1.000) and Pg (OR = 2.773, 95% CI = 0.510–3.370) levels, the number of oocytes (OR = 1.254, 95% CI = 0.894–1.472) and MII oocytes (OR = 1.238, 95% CI = 0.747–1.217) were risk factors for OHSS. However, a multivariate regression analysis showed that the total number of follicles (OR = 1.124, 95% CI = 1.027–1.230) was the only predictive factor for the occurrence of OHSS.
Conclusion. The study demonstrated that the follicle count measured on the day of hCG administration was the only predictive factor for the occurrence of OHSS. This provides basic guidance to clinicians on the prevention of the complication when using assisted reproductive technologies (ART).

Key words

in vitro fertilization, ovarian hyperstimulation syndrome, human chorionic gonadotropin

References (21)

  1. Nastri CO, Ferriani RA, Rocha IA, Martins WP. Ovarian hyperstimulation syndrome: Pathophysiology and prevention. J Assist Reprod Genet. 2010;27(2–3):121–128.
  2. Nastri CO, Teixeira DM, Moroni RM, Leitão VM, Martins WP. Ovarian hyperstimulation syndrome: Pathophysiology, staging, prediction and prevention. Ultrasound Obstet Gynecol. 2015;45(4):377–393.
  3. Kaiser UB. The pathogenesis of the ovarian hyperstimulation syndrome. N Engl J Med. 2003;349(8):729–732.
  4. Busso C, Fernández-Sánchez M, García-Velasco JA, et al. The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: A randomized, double-blind, placebo-controlled trial. Hum Reprod. 2010;25(4):995–1004.
  5. Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): A review. Hum Reprod Update. 2002;8(6):559–577.
  6. Smith V, Osianlis T, Vollenhoven B. Prevention of ovarian hyperstimulation syndrome: A review. Obstet Gynecol Int. 2015;2015:514159.
  7. Varma TR, Patel RH. Ovarian hyperstimulation syndrome: A case history and review. Acta Obstet Gynecol Scand. 1988;67(7):579–584.
  8. Golan A, Ron-el R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome: An update review. Obstet Gynecol Surv. 1989;44(6):430–440.
  9. Aboulghar M. Prediction of ovarian hyperstimulation syndrome (OHSS): Estradiol level has an important role in the prediction of OHSS. Hum Reprod. 2003;18(6):1140–1141.
  10. Orvieto R. Prediction of ovarian hyperstimulation syndrome: Challenging the estradiol mythos. Hum Reprod. 2003;18(4):665–667.
  11. König E, Bussen S, Sütterlin M, Steck T. Prophylactic intravenous hydroxyethyle starch solution prevents moderate-severe ovarian hyperstimulation in in-vitro fertilization patients: A prospective, randomized, double-blind and placebo-controlled study. Hum Reprod. 1998;13(9):2421–2424.
  12. Nargund G, Hutchison L, Scaramuzzi R, Campbell S. Low-dose HCG is useful in preventing OHSS in high-risk women without adversely affecting the outcome of IVF cycles. Reprod Biomed Online. 2007;14(6):682–685.
  13. O’Donovan O, Chami AA, Davies M. Ovarian hyperstimulation syndrome. Obstet Gynaecol Reprod Med. 2015;25(2):43–48.
  14. de Mouzon J, Goossens V, Bhattacharya S, et al; European IVF-monitoring (EIM) Consortium, for the European Society of Human Reproduction and Embryology (ESHRE). European IVF-monitoring (EIM) Consortium, for the European Society of Human Reproduction and Embryology (ESHRE): Assisted reproductive technology in Europe, 2006: Results generated from European registers by ESHRE. Hum Reprod. 2010;25(8):1851–1862.
  15. Aboulghar MA, Mansour RT. Ovarian hyperstimulation syndrome: Classifications and critical analysis of preventive measures. Hum Reprod Update. 2003;9(3):275–289.
  16. Mocanu E, Redmond ML, Hennelly B, Collins C, Harrison R. Odds of ovarian hyperstimulation syndrome (OHSS): Time for reassessment. Hum Fertil (Camb). 2007;10(3):175–181.
  17. Mathur RS, Akande AV, Keay SD, Hunt LP, Jenkins JM. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril. 2000;73(5):901–907.
  18. Humaidan P, Quartarolo J, Papanikolaou EG. Preventing ovarian hyperstimulation syndrome: Guidance for the clinician. Fertil Steril. 2010;94(2):389–400.
  19. Abstracts of the 29th Annual Meeting of the European Society of Human Reproduction and Embryology. London, UK. July 7–10, 2013. Hum Reprod. 2013;28(Suppl 1):370.
  20. Kwan I, Bhattacharya S, Kang A, Woolner A. Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI). Cochrane Database Syst Rev. 2014;8:CD005289.
  21. Aramwit P, Pruksananonda K, Kasettratat N, Jammeechai K. Risk factors for ovarian hyperstimulation syndrome in Thai patients using gonadotropins for in vitro fertilization. Am J Health Syst Pharm. 2008;65(12):1148–1153.
© Wroclaw Medical University